Table 2. Median PFS, OS, ORR and DCR on EGFR-TKI treatment in advanced-stage NSCLC patients with classic EGFR mutations.
| N | Months | (95% CI) | P-value | |
|---|---|---|---|---|
|
Median PFS | ||||
| All patients | 98a | 12.2 | (10.8–13.5) | |
| Exon 19 | 75 | 12.6 | (11.2–14.1) | 0.26 |
| Exon 21 | 23 | 12.0 | (7.5–16.6) | |
|
Median OS | ||||
| All patients | 107b | 26.4 | (22.8–30.1) | |
| Exon 19 | 79 | 28.2 | (21.8–34.6) | 0.04 |
| Exon 21 | 28 | 21.0 | (20.4–21.6) | |
| N | % | P-value | ||
|
ORR | ||||
| All patients | 94c | 84.0% | ||
| Exon 19 | 70 | 84.3% | 0.91 | |
| Exon 21 | 24 | 83.3% | ||
|
DCR | ||||
| All patients | 94c | 95.7% | ||
| Exon 19 | 70 | 97.1% | 0.25 | |
| Exon 21 | 24 | 91.7% | ||
Abbreviations: CI=confidence interval; DCR=disease control rate; EGFR=epidermal growth factor receptor; NSCLC=non-small-cell lung cancer; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; TKI=tyrosine kinase inhibitor.
a
For 13 patients, data on PFS on EGFR-TKI treatment were incomplete (Supplementary Table 2).
b
For 4 patients, data on OS on EGFR-TKI treatment were incomplete (Supplementary Table 3).
c
For 17, patients data on response on EGFR-TKI treatment were incomplete (Supplementary Table 4).